In addition, targeting TGF-β1-Smad7 signalling is applicable to the fibrosis of other organs, such as lung fibrosis [34], and thus, MSC-Smad7 cell therapy should open a new strategy for anti-fibrosis therapy. Here, SMAD7 is linked to pulmonary fibrosis.